The Latest Breaking News from ATAI

Eli Lilly Is Buying AtaiBeckley in $2.8 Billion Deal. What It Means for LLY Stock

Eli Lilly stock rallies on a $2.8 billion acquisition of AtaiBeckley. Here’s why the deal is bullish for LLY shares.

Barchart · Jul 16

Stock Market Today: Dow Futures Rise, S&P 500 Falls As Trump Says Iran Wants To Negotiate— AtaiBeckley, J B Hunt, AST SpaceMobile in Focus (UPDATED)

(Editor’s note: The lede, futures, ETFs and economic data were updated.)

Benzinga · Jul 16

These 3 Psychedelic Stocks Activated After Trump's Executive Order

Psychedelic drugs could get a big boost thanks to a recent executive order, and these firms all have promising candidates in line.

MarketBeat · Apr 27

North Carolina Wants to ‘Lead the Nation’ in Psychedelics. Here’s 1 ‘Strong Buy’ Stock to Buy Now.

As policy meets potential in North Carolina, Atai Life Sciences could be a solid portfolio addition now.

Barchart · Oct 24, 2025

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside

Needham on Monday initiated coverage on Atai Life Sciences NV (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on developing treatments for mental health.

Benzinga · Oct 13, 2025

Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients

Atai Life Sciences (NASDAQ:ATAI) and Beckley Psytech Limited, a private clinical-stage biopharmaceutical company, released data from a proof-of-concept study investigating a two-dose induction regimen of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD).

Benzinga · Sep 23, 2025

This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Benzinga · Jul 29, 2025

Why Is ATAI Life Sciences Stock Trading Lower On Monday?

Amid a surge in research targeting cognitive disorders, the pharmaceutical industry is witnessing a wave of pivotal trial results that could reshape schizophrenia treatment paradigms. As biotech firms race to develop innovative therapies, Recognify Life Sciences steps into the spotlight with new findings from its latest clinical trial.

Benzinga · Jul 28, 2025

Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were mixed, with the Dow Jones index gaining over 250 points on Tuesday.

Benzinga · Jul 1, 2025

2 ‘Strong Buy’ Psychedelic Stocks to Scoop Up ASAP

Two psychedelic-focused stocks stand to benefit after the FDA designated psychedelics as a top review priority.

Barchart · May 27, 2025